Wells Fargo & Company Lowers Agilent Technologies (NYSE:A) Price Target to $155.00

Agilent Technologies (NYSE:A) had its price objective decreased by research analysts at Wells Fargo & Company from $157.00 to $155.00 in a report issued on Monday, Marketbeat Ratings reports. The firm presently has an “overweight” rating on the medical research company’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 9.21% from the company’s current price.

Several other research firms have also recently weighed in on A. UBS Group increased their price objective on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. TD Cowen increased their price objective on Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Bank of America increased their price objective on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Citigroup increased their price objective on Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, Barclays reduced their price objective on Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating for the company in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $143.14.

Agilent Technologies Stock Down 1.4 %

Shares of Agilent Technologies stock opened at $141.93 on Monday. The stock has a market capitalization of $40.78 billion, a P/E ratio of 32.11, a PEG ratio of 4.46 and a beta of 1.07. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57. The stock has a 50 day moving average price of $137.15 and a two-hundred day moving average price of $136.60. Agilent Technologies has a 12-month low of $124.16 and a 12-month high of $155.35.

Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The firm had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.67 billion. During the same quarter in the prior year, the business earned $1.38 earnings per share. The company’s revenue was up .8% on a year-over-year basis. Equities analysts expect that Agilent Technologies will post 5.56 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 19.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.33% of the company’s stock.

Institutional Trading of Agilent Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA boosted its holdings in Agilent Technologies by 5.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock valued at $1,952,832,000 after acquiring an additional 809,149 shares during the last quarter. FMR LLC boosted its holdings in Agilent Technologies by 62.2% during the third quarter. FMR LLC now owns 1,287,665 shares of the medical research company’s stock worth $191,193,000 after buying an additional 493,947 shares during the last quarter. Worldquant Millennium Advisors LLC bought a new position in Agilent Technologies during the third quarter worth about $49,449,000. Marshall Wace LLP boosted its holdings in Agilent Technologies by 48.6% during the second quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock worth $124,073,000 after buying an additional 313,155 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in Agilent Technologies by 63.3% during the third quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock worth $87,075,000 after buying an additional 227,431 shares during the last quarter. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.